Parkman Healthcare Partners LLC Has $2.59 Million Stock Holdings in Insmed Incorporated (NASDAQ:INSM)

Parkman Healthcare Partners LLC lowered its position in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) by 55.9% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 35,433 shares of the biopharmaceutical company's stock after selling 44,838 shares during the quarter. Parkman Healthcare Partners LLC's holdings in Insmed were worth $2,587,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Darwin Global Management Ltd. purchased a new stake in Insmed during the 2nd quarter worth $237,076,000. Principal Financial Group Inc. boosted its holdings in Insmed by 12.9% in the 3rd quarter. Principal Financial Group Inc. now owns 1,871,890 shares of the biopharmaceutical company's stock worth $136,648,000 after acquiring an additional 214,130 shares during the period. Clearbridge Investments LLC boosted its holdings in Insmed by 76.8% in the 2nd quarter. Clearbridge Investments LLC now owns 1,644,948 shares of the biopharmaceutical company's stock worth $110,212,000 after acquiring an additional 714,539 shares during the period. Vestal Point Capital LP boosted its holdings in Insmed by 113.3% in the 3rd quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company's stock worth $116,800,000 after acquiring an additional 850,000 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Insmed by 10.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,444,266 shares of the biopharmaceutical company's stock valued at $105,431,000 after purchasing an additional 137,670 shares during the period.

Wall Street Analyst Weigh In

INSM has been the subject of a number of analyst reports. UBS Group upped their price objective on shares of Insmed from $78.00 to $84.00 and gave the company a "buy" rating in a research report on Friday, August 9th. Truist Financial reissued a "buy" rating and issued a $105.00 price target (up previously from $100.00) on shares of Insmed in a report on Friday, November 1st. TD Cowen increased their target price on Insmed from $75.00 to $98.00 and gave the company a "buy" rating in a research note on Friday, August 9th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Insmed in a research note on Monday, September 9th. Finally, StockNews.com downgraded shares of Insmed from a "hold" rating to a "sell" rating in a research note on Friday, August 9th. One investment analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $83.67.

Insider Buying and Selling at Insmed

In other Insmed news, insider Martina M.D. Flammer sold 13,436 shares of the business's stock in a transaction on Monday, September 16th. The shares were sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the sale, the insider now directly owns 106,134 shares of the company's stock, valued at $7,951,559.28. The trade was a 11.24 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Michael Alexander Smith sold 27,871 shares of the company's stock in a transaction on Friday, September 13th. The shares were sold at an average price of $74.35, for a total value of $2,072,208.85. Following the transaction, the insider now directly owns 67,856 shares in the company, valued at $5,045,093.60. The trade was a 29.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 78,882 shares of company stock valued at $5,765,446. Corporate insiders own 4.60% of the company's stock.

Insmed Price Performance

INSM traded up $2.93 during trading on Wednesday, reaching $75.36. The stock had a trading volume of 1,539,855 shares, compared to its average volume of 2,214,903. The stock has a 50 day moving average of $72.21 and a two-hundred day moving average of $69.01. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The firm has a market capitalization of $13.48 billion, a price-to-earnings ratio of -13.05 and a beta of 1.10. Insmed Incorporated has a 1-year low of $21.92 and a 1-year high of $80.53.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The business had revenue of $93.40 million for the quarter, compared to analysts' expectations of $93.36 million. During the same quarter in the previous year, the business posted ($1.10) EPS. The company's quarterly revenue was up 18.1% compared to the same quarter last year. As a group, equities analysts anticipate that Insmed Incorporated will post -5.44 EPS for the current fiscal year.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.